Key result
Percutaneous pulmonary valve implantation with the Venus P-valve system achieved a 96% freedom from all-cause mortality and reintervention at 5 years.
Why the study?
Percutaneous pulmonary valve implantation with the self-expandable Venus P-valve system is promising for PR and native RVOT, but limited data exist regarding its midterm outcomes.
Does percutaneous pulmonary valve implantation with the Venus P-valve system improve outcomes in patients with moderate or severe pulmonary regurgitation after surgical RVOT repair?
Cohort (n=55)
Yes
Does percutaneous pulmonary valve implantation with the Venus P-valve system improve outcomes in patients with moderate or severe pulmonary regurgitation after surgical RVOT repair?
Percutaneous pulmonary valve implantation with the Venus P-valve system provides sustained 5-year symptomatic and hemodynamic benefits with high freedom from mortality and reintervention in patients with severe pulmonary regurgitation and an enlarged native RVOT.
May support percutaneous implantation in enlarged native RVOT; leaves open randomized confirmation versus surgery.
BACKGROUND: Percutaneous pulmonary valve implantation (PPVI) with the self-expandable Venus P-valve system is a promising treatment for patients with pulmonary regurgitation (PR) and a native right ventricular outflow tract (RVOT). However, limited data is available regarding its midterm outcomes. This study assessed the midterm clinical and echocardiographic outcomes following Venus P-valve implantation. METHODS: From 2013 to 2018, 55 patients with moderate or severe PR after surgical RVOT repair with a transannular or RVOT patch were consecutively enrolled from six hospitals in China. Five-year clinical and echocardiographic outcomes were collected and evaluated. The primary endpoint was a freedom from all-cause mortality and reintervention. RESULTS: At 5 years, the primary endpoint was met for 96% of patients, corresponding to a freedom from all-cause mortality of 96% (95% confidence interval [CI]: 86%-99%) and freedom from reintervention of 98% (95% CI: 87%-100%). Endocarditis was reported in five patients (four patients within 1 year and one patient at 5 years) following PPVI. Transpulmonary gradient and stent orifice diameter remained stable compared to at discharge (p＞0.05). No paravalvular leak was reported while only 1 patient gradually increased to moderate PR during follow-up. Significant improvement of RV diameter and LVEF (p＜0.001) sustained over the 5-year follow-up, in consistent with remarked improved New York Heart Association(NYHA) functional class (p＜0.001). CONCLUSION: The 5-year results of the China VenusP Study demonstrated the midterm benefits of Venus P-valve implantation in the management of patients with severe PR with an enlarged native RVOT by providing sustained symptomatic and hemodynamic improvement.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2023) conducted a cohort in Pulmonary regurgitation with an enlarged native right ventricular outflow tract (n=55). Percutaneous pulmonary valve implantation with the Venus P-valve system was evaluated on Freedom from all-cause mortality and reintervention. Percutaneous pulmonary valve implantation with the Venus P-valve system achieved a 96% freedom from all-cause mortality and reintervention at 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: